Drilldown: Medicines

None · Codeine · 1,4-Butanediol · 1B-LSD · 1cP-LSD · 1P-LSD · 1V-LSD · 2-AI · 2-FA · 2-FDCK · 2-FMA · 25B-NBOH · 25B-NBOMe · 25C-NBOH · 25C-NBOMe · 25I-NBOH · 25I-NBOMe · 25N-NBOMe · 2C-B · 2C-B-FLY

Other values:

Search

None (1) · (multiple, generic dominant) (1) · Nexus, Eroxan (historical, late-1980s through mid-1990s) (1) · Tylenol, Panadol (international), Ofirmev (IV); huge OTC presence (1)

2C-x series (1) · Analgesic (2) · Opioid (2) · Phenethylamine (1) · Prodrug (1) · Psychedelic (1) · [[:Category:Analgesics|Non-opioid analgesic]] (1) · [[:Category:Antipyretics|Antipyretic]] (1)

None (1) · 5-HT2A partial agonist (1) · Mu-opioid receptor agonist; prodrug (metabolized to morphine) (1) · Prodrug; converted to [[Morphine|morphine]] by [[Enzyme:CYP2D6|CYP2D6]] for analgesic action. (1)

None (2) · Mild to moderate pain; cough suppression (low-dose). (1) · '"`UNIQ--vote-000006A2-QINU`"', '"`UNIQ--vote-000006A3-QINU`"', '"`UNIQ--vote-000006A4-QINU`"' (1)

None (2) · 325-1000 mg PO every 4-6 hours as needed; maximum 4 g/d in healthy adults, 3 g/d in regular users or hepatic risk; pediatric 10-15 mg/kg every 4-6 hours (1) · Adult: 15–60 mg every 4 hours as needed. (1)

None (2) · 325, 500, 650 mg tablets; 80, 160 mg chewables; 160 mg/5 mL pediatric liquid; 325 mg suppository; 1000 mg/100 mL IV (Ofirmev); fixed-dose combinations with opioids, decongestants, antihistamines (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)

None (2) · 360 mg/day (1) · 4 g/d in healthy adults; 3 g/d conservative limit; 2 g/d in cirrhosis or chronic alcohol use (1)

None (1) · insufflated (1) · IV (1) · Oral (2) · PO (only formulation marketed in the US). (1) · PR (1) · rectal (1)

None (1) · 30–60 min (PO) (1) · 45-75 min (oral) (1) · PO: 30-60 minutes; IV: minutes (1)

None (1) · 4-6 hours (1) · 4-8 h (1) · 4–6 hours (1)

None (1) · 1-3 hours (normal liver); markedly prolonged in overdose with glutathione depletion'"`UNIQ--ref-000006A5-QINU`"' (1) · 2.5–3 hours (1) · Not well characterized (1)

None (1) · Not well characterized (1) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1) · ~85-98% (oral)'"`UNIQ--ref-000006A6-QINU`"' (1)

None (1) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) · Long the preferred analgesic-antipyretic in pregnancy; recent observational studies have raised speculative neurodevelopmental signals that remain under investigation.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Not established (1)

None (1) · OTC and [[USLegal:Prescription only|Rx-only]] (IV, combination products) in US (1) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1) · [[USLegal:DEA Schedule I|Schedule I]] (United States) (1)